A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy

BACKGROUND: The endothelin system is implicated in the pathogenesis of melanoma. We evaluated the effects of bosentan - a dual endothelin receptor antagonist - in patients receiving first-line dacarbazine therapy for stage IV metastatic cutaneous melanoma in a phase 2, proof-of-concept study. RESULT...

Descripción completa

Detalles Bibliográficos
Autores principales: Kefford, Richard F, Clingan, Philip R, Brady, Benjamin, Ballmer, Andrea, Morganti, Adele, Hersey, Peter
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2856553/
https://www.ncbi.nlm.nih.gov/pubmed/20350333
http://dx.doi.org/10.1186/1476-4598-9-69

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2856553/
https://www.ncbi.nlm.nih.gov/pubmed/20350333
http://dx.doi.org/10.1186/1476-4598-9-69

Ejemplares similares